Search results
Results From The WOW.Com Content Network
Life expectancy with cardiomyopathy varies based on many factors, including stage and class of cardiomyopathy, with life expectancy being lower for those with severe, symptomatic heart failure (stage D). A 2019 analysis showed that the overall five-year survival rate for people with heart failure was about 50%.
We found that a 55.9% mortality rate in such patients in the first five years, and a 65.8% mortality rate at 15 years. Patients with dilated cardiomyopathy have a poor prognosis, so more accurate risk stratification and personalized therapy may considerably improve outcomes.
Without a transplant, the survival rates are poor. DCM has many causes and all of them affect the ventricular function to a varying degree. While most patients with DCM have symptoms, a few patients may be asymptomatic because of the compensatory mechanisms.
Dilated cardiomyopathy (DCM) is a leading cause of heart failure and life-threatening ventricular arrhythmias (LTVA). ... age of disease onset, and rate of progression, ... Anand I., Maggioni A., Burton P., Sullivan M.D., et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation. 2006;113:1424–1433. doi: 10. ...
From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.
Moreover, prognosis is affected by progressive amyloid deposition in other organs. 66 – 68 Cardiac transplantation for amyloidosis has a bleak prognosis, with 5-year survival of only 20% to 30%. 69 In a small case series of 10 patients with cardiac amyloidosis who underwent cardiac transplantation, 4 patients developed amyloid deposition in ...
Introduction: Dilated cardiomyopathy (DCM) is associated with a significant mortality risk, with untreated cases showing a five-year survival rate of just 50%. However, there is a scarcity of data on how DCM-related mortality rates have changed over time.
During follow-up period of 6.9+/-4.8 years, 62 patients died and 1 patient had a heart transplant. The survival rate at 5 and 10 years was 60.9% and 34.8%, respectively, in group A patients, and 80.9% and 65.3%, respectively, in group B patients (p=0.0079).
This nationwide study of patients with DCM demonstrates that longer disease duration is associated with worse prognosis. Co‐morbidities are more common in long‐standing HF than in recent‐onset HF and are associated with worse outcome.
Results: A comparatively large cohort of 122 recovered DCM patients from 10,029 DCM patients was analyzed. During a median follow-up duration of 53.5 months, the relapse rate among recovered DCM patients was 15.6% (19/122).